Special edition – Article 1

Generic prescribing –
what are the benefits and
what are the risks?

With the recent Government consultation on generic substitution and the impending patent expiry for the angiotensin II receptor blocker (ARB) class, which began with losartan (March 2010), it is appropriate to review the current debates and policies in development on generic prescribing with particular emphasis on the benefits and risks in different therapy areas.

Download the PDF of Article 1 here